Michael W. Weiner, United States of America

University of California San Francisco (UCSF) Radiology
Dr. Weiner has been conducting research for more than 50 years and is Principal Investigator of the Alzheimer's Disease Neuroimaging Initiative (ADNI), and the BrainHealthRegistry.org, an internet-based registry with the overall goal of accelerating development of effective treatments for brain diseases. Dr. Weiner’s research largely focuses on treatment to slow progression in Alzheimer’s disease, and on early detection and prevention. Dr. Weiner completed his M.D at SUNY Upstate Medical Center Syracuse in 1965, his internship and residency at Mt. Sinai Hospital in 1967, and a residency and clinical fellowship in at Yale-New Haven Medical Center in 1968. He had various fellowships, earning Assistant Professorship at Stanford in 1974, and Associate Professorship at UCSF in 1980 when he was one of the first to perform MRS on an intact animal. He subsequently pursued development of MRI/MRS as a clinical tool. In 1983, he established the Magnetic Resonance Unit at the San Francisco VA Medical Center (which became the Center for Imaging of Neurodegenerative Diseases in 2000, and VA Advanced Imaging Research Center in 2020). Since 1990, he’s been a Professor in Radiology, Medicine, Psychiatry and Neurology at UCSF. Dr. Weiner has published over 900 peer-reviewed articles, holds 19 separate research grants, and has received numerous honors. In 2010, he was named one of the “Rock Stars of Science” in GQ magazine, and received the Gold Medal of Paul Sabatier University and the City of Toulouse, France. In 2011, he received the Ronald and Nancy Reagan Award for Research from the Alzheimer’s Association; in 2013, the Potamkin Prize for Research in Picks Disease, Alzheimer’s Disease and other Neurodegenerative Disorders from the American Association of Neurology and the American Brain Foundation; in 2014 the Distinguished Investigator Award from Academy of Radiology Research; in 2018, an Honorary Professorship Award from Australian Catholic University; and in 2019, a Docteur Honoris Causa Degree from Paul Sabatier University, Toulouse, France.

Moderator of 1 Session

LIVE SYMPOSIUM DISCUSSION

LIVE DISCUSSION - FLUID BIOMARKERS 1

Date
10.03.2021, Wednesday
Session Time
17:00 - 17:30
Session Icon
Live

Presenter of 3 Presentations

VALIDATING PLASMA TESTS FOR AMYLOID, TAU, AND NEURODEGENERATION USING THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE (ADNI): PLASMA SAMPLES ARE AVAILABLE UPON REQUEST

Session Name
Session Type
SYMPOSIUM
Date
10.03.2021, Wednesday
Session Time
12:00 - 14:00
Room
On Demand Symposia A
Lecture Time
12:00 - 12:15
Session Icon
On-Demand

Abstract

Abstract Body

Plasma assays for amyloid beta, phosphorylated tau, neurofilament light and other markers are now the most innovative and exciting development in the field of diagnostics for Alzheimer’s Disease (AD). The Alzheimer’s Disease Neuroimaging Initiative is in an ideal position to help validate and compare these assays, because plasma samples have been banked on over 2,270 participants at each longitudinal visit. ADNI data on plasma assays will be discussed.

The goal of ADNI (see ADNI-info.org) has been to standardize and validate MRI and PET imaging and blood/CSF biomarkers for Alzheimer’s treatment trials. Overall, we have enrolled a total of 2,272 participants: Elders with mild cognitive impairment (MCI) (n=1043); Dementia (n=397); Normal Controls (n=518) and 301 Controls with cognitive complaints. Participants have annual clinical visits, neuropsychological assessments, MRI (structural, perfusion, diffusion-tensor and task-free, resting-state fMRI), FDG PET, both amyloid and tau PET, blood and urine, and CSF (abeta, tau, ptau and other analytes), and whole genome sequencing. All ADNI data is available to all scientists in the world, on USC/LONI/ADNI, without embargo. A major interest in the field is to identify predictors of future risk for cognitive decline, and ADNI provides the largest available data set for analyses of this type. Over 2,200 papers have been published on ADNI.

Plasma, DNA, RNA, RBC pellets, and CSF samples can be requested online at http://adni.loni.usc.edu/data-samples/access-data/

ADNI will validate diagnostic techniques, including the new plasma assays, which can be used for diagnosis, and to measure the effects of treatments which slow progression and prevent AD.

Hide